For the quarter ending 2025-09-30, AMRX made $784,513,000 in revenue. $18,132,000 in net income. Net profit margin of 2.31%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Net revenue | 784,513,000 | 724,508,000 | 695,420,000 | 694,854,500 |
| Cost of goods sold | 510,539,000 | 438,255,000 | 439,529,000 | 444,388,000 |
| Gross profit | 273,974,000 | 286,253,000 | 255,891,000 | 250,466,500 |
| Selling, general and administrative | 137,815,000 | 124,266,000 | 118,288,000 | 120,641,000 |
| Research and development | 63,352,000 | 47,964,000 | 40,040,000 | 46,781,500 |
| Intellectual property legal development expenses | 2,437,000 | 2,017,000 | 1,767,000 | 1,461,250 |
| Change in fair value of contingent consideration | - | - | - | -33,333.333 |
| Restructuring and other charges | 143,000 | 1,024,000 | 571,000 | 981,500 |
| (credit) charges related to legal matters, net | 0 | 390,000 | - | -48,071,000 |
| Other operating income | 117,000 | 0 | -5,122,000 | - |
| Operating income (loss) | 70,344,000 | 111,372,000 | 100,347,000 | 32,523,500 |
| Interest expense, net | -62,814,000 | -65,101,000 | -56,939,000 | -63,682,500 |
| Foreign exchange (loss) gain, net | -3,431,000 | 8,256,000 | 4,247,000 | -4,429,000 |
| Decrease (increase) in tax receivable agreement liability | 20,808,000 | -4,420,000 | -10,687,000 | -12,954,500 |
| Loss on refinancing | -31,365,000 | - | - | - |
| Other income, net | 1,235,000 | 1,604,000 | 518,000 | 3,122,000 |
| Total other expense, net | -75,567,000 | -59,661,000 | -62,861,000 | -77,944,000 |
| Income (loss) before income taxes | -5,223,000 | 51,711,000 | 37,486,000 | -45,420,500 |
| (benefit from) provision for income taxes | -23,355,000 | 16,101,000 | 12,868,000 | 5,789,500 |
| Net income (loss) | 18,132,000 | 35,610,000 | 24,618,000 | -51,210,000 |
| Less net (income) loss attributable to non-controlling interests | - | - | - | 43,493,500 |
| Net loss attributable to amneal pharmaceuticals, inc. before accretion of redeemable non-controlling interest | - | - | - | -29,221,500 |
| Net loss attributable to amneal pharmaceuticals, inc | - | - | - | -29,221,500 |
| Basic (in dollars per share) | 0.01 | 0.07 | 0.04 | -0.2 |
| Basic (in shares) | 314,168,000 | 313,739,000 | 311,054,000 | -154,893,000 |
| Diluted (in dollars per share) | 0.01 | 0.07 | 0.04 | -0.2 |
| Diluted (in shares) | 324,754,000 | 322,363,000 | 323,961,000 | -159,813,000 |
Amneal Pharmaceuticals, Inc. (AMRX)
Amneal Pharmaceuticals, Inc. (AMRX)